Myoinositol is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab reduces tumor edema, we asked whether the Myoinositol concentration changes during therapy.
We used 1H-MRS to measure the Myoinositol concentrations in the tumor and contralateral control of patients with recurrent glioblastomas treated with Bevacizumab (n=30) and CCNU/VM26 (n=9).
Pre-therapeutic Myoinositol concentrations in the contralateral control were predictive of overall survival in patients treated with Bevacizumab. Furthermore our data confirm that recurrent glioblastoma show a strong metabolic reaction to Bevacizumab and support the hypothesis that Myoinositol might be a marker for early tumor cell invasion.